Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1882 - A Phase II Trial of Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site

Head and Neck Cancers


Yoshinori Imamura


Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287


Y. Imamura1, N. Kiyota2, K. Tanaka3, H. Hayashi3, I. Ota4, K. Nario4, S. Hirano5, A. Arai5, S. Iwae6, T. Onoe7, S. Minami8, T. Shimada8, K. Yane9, T. Yamazaki10, Y. Nagatani1, M. Toyoda1, N. Otsuki11, K. Nibu11, H. Minami1

Author affiliations

  • 1 Medical Oncology/hematology, Kobe University Hospital, 650-0017 - Kobe/JP
  • 2 Medical Oncology/hematology, Kobe University Hospital, Kobe/JP
  • 3 Medical Oncology, Kindai University Faculty of Medicine, 589-8511 - Osaka/JP
  • 4 Otolaryngology Head And Neck Surgery, Nara Medical University, Kashihara/JP
  • 5 Otorhinolaryngology, Kyoto Prefectural University of Medicine, Kyoto/JP
  • 6 Head And Neck Surgery, Hyogo Cancer Center, Akashi/JP
  • 7 Medical Oncology, Hyogo Cancer Center, 673-8558 - Akashi/JP
  • 8 Otolaryngology, National Hospital Organization Tokyo Medical Center, Tokyo/JP
  • 9 Otolaryngology, Nara Hospital, Faculty of Medicine, Kindai University, Nara/JP
  • 10 Head And Neck Cancer Oncology, Miyagi Cancer Center, 981-1293 - Natori/JP
  • 11 Otolaryngology-head And Neck Surgery, Kobe University Hospital, 650-0017 - Kobe/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1882


Due to the rarity and heterogeneity of recurrent and/or metastatic head and neck non-squamous cell carcinoma (R/M HN non-SCC), no standard chemotherapy for this condition has yet been established. This multicenter phase II trial evaluated the efficacy and safety of docetaxel and cisplatin combination (DC) in R/M HN non-SCC.


Eligibility criteria were R/M HN non-SCC; progressive disease within the last 6 months; no prior systemic therapy, or interval of at least 24 weeks since the last induction chemotherapy or chemoradiotherapy with curative intent; measurable disease; and ECOG performance status of 0 or 1. Patients (pts) received docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles. The primary endpoint was objective response rate (ORR).


From Nov 2012 to Oct 2016, a total of 23 pts were enrolled, characterized as 15 females, median age 57 years (range, 32-76), and 96% metastatic. Among 22 evaluable pts, ORR was 45.5% (95% confidential interval [CI], 24.4-67.8%), and the lower bound of the 95% CI of 24.4% exceeded the predefined hypothesis of 10%. ORRs according to primary tumor site and histology are shown in the table below. With a median follow-up period of 18.8 months, median progression-free survival and overall survival were 6.7 and 20.1 months, respectively. Grade 3/4 adverse events included neutropenia (91%), febrile neutropenia (FN) (39%), anemia (22%), appetite loss (17%), and fatigue (13%). The FN rate was significantly lower in the pts with prophylactic antibiotics (57 vs 11%, P = 0.04). No treatment-related deaths were observed.Table: 1066P

Objective response rates according to primary tumor site and histology

Adenoid cystic carcinomaAadenocarcinoma, not otherwise specifiedSalivary duct carcinomaSebaceous carcinomaMucoepidermoid carcinomaNUT midline carcinomaAcinic cell carcinomaTotal
Salivary gland2/42/32/30/16/11
Nasal cavity/paranasal sinus1/31/3
Oral cavity/lip1/10/11/2

complete response


This phase II study of DC met its primary endpoint. This DC regimen is effective and represents a new treatment option in the treatment of progressive R/M HN non-SCC, although prophylactic antibiotics for FN should be considered.

Clinical trial identification


Legal entity responsible for the study

Kobe University Hospital.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.